Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

18.35 -0.12 (-0.65%)
Streaming Delayed Price Updated: 9:43 AM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,901
Open 18.41
Bid (Size) 18.28 (100)
Ask (Size) 18.40 (100)
Prev. Close 18.47
Today's Range 18.24 - 18.52
52wk Range 14.62 - 19.67
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗
This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+19.3%
+19.3%
1 Month
+8.3%
+8.3%
3 Month
+19.3%
+19.3%
6 Month
+19.3%
+19.3%
1 Year
+19.3%
+19.3%

More News

Read More
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium (DFTX) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Participate at Upcoming Investor Conferences
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Appoints Roger Adsett to Board of Directors
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
2026 Asset Growth: Why Federal Compliance Is the New Metric
From Equity Insider
Via GlobeNewswire

Frequently Asked Questions

Is Definium Therapeutics, Inc. - Common Shares publicly traded?
Yes, Definium Therapeutics, Inc. - Common Shares is publicly traded.
What exchange does Definium Therapeutics, Inc. - Common Shares trade on?
Definium Therapeutics, Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Definium Therapeutics, Inc. - Common Shares?
The ticker symbol for Definium Therapeutics, Inc. - Common Shares is DFTX on the Nasdaq Stock Market
What is the current price of Definium Therapeutics, Inc. - Common Shares?
The current price of Definium Therapeutics, Inc. - Common Shares is 18.35
When was Definium Therapeutics, Inc. - Common Shares last traded?
The last trade of Definium Therapeutics, Inc. - Common Shares was at 03/26/26 09:43 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.